EGFR mutation, recurrence-free survival, disease-free survival, TP53 mutation, recurrence prediction, cox model
Non-small cell lung cancer, NSCLC, immune checkpoint inhibitors, anti-TIGIT monoclonal antibody, PD-L1 inhibitor, atezolizumab, tiragolumab, cancer immunotherapy
Small cell lung cancer, transformation, rebiopsy, tumor surface protein, antibody drug conjugate
Non-small-cell lung cancer, neoadjuvant therapy, adjuvant therapy, immunotherapy, Clinical trial
occult lymph node, non-small cell lung cancer, genomic profile, EGFR mutations, ALK rearrangements
EGFR mutation, recurrence-free survival, disease-free survival, TP53 mutation, recurrence prediction
second primary lung cancer, smoking history, multiple primary lung cancer, consolidation-to-tumor ratio, genetic mutation
